This aligns with published narrative syntheses describing Tirzepatide’s dual GIP/GLP-1 receptor mechanism as a key driver of its robust weight-loss effects across diverse clinical trials and obesity-management settings [23]. The gene discussed is GIP; the disease is obesity disorder.